Curiosity-driven basic research: the argument for funding science without obvious targets

Full analysis

Peter Attia closes a survey of medical breakthroughs — statins, ACE inhibitors, PCR, CRISPR, GLP-1 drugs — by making an explicit argument about science funding and policy. In almost every case, the foundational discovery was made by a researcher who was not trying to cure a disease: someone studying jellyfish bioluminescence, life in boiling hot springs, or DNA patterns in salt-pond microbes. Had these projects been evaluated by a panel asking "what disease will this cure and on what timeline," many would have failed to get funded. The NIH declined to fund Douglas Prasher to continue working on the green fluorescent protein gene he had cloned, a decision Attia describes as the system failing in exactly the way he is warning against.

His argument is not that all basic science deserves funding regardless of quality — peer review and rigor matter — but that requiring near-term translational impact as a criterion systematically screens out the research most likely to produce transformative tools. He acknowledges survivorship bias: almost none of today's curiosity-driven projects will become the next GFP or CRISPR. But his point is that we are demonstrably bad at predicting which ones will, and applying the wrong filter discards what we cannot yet recognize. For readers involved in healthcare policy, philanthropy, or simply interested in where the next generation of medicines may come from, the argument has direct bearing on decisions about research support.